News Researchers Find OCT Imaging Technique a Reliable Tool for Multiple Sclerosis Assessment Researchers Find OCT Imaging Technique a Reliable Tool for Multiple Sclerosis Assessment by Malika Ammam, PhD | September 11, 2015 Share this article: Share article via email Copy article link In a newly published study in the PLOS One journal entitled “Reliability of Intra-Retinal Layer Thickness Estimates“, researchers from Germany explored the precision and reliability of a medical imaging technique named optical coherence tomography (OCT) in measurements of thickness of different intra-retinal layers in patients with multiple sclerosis (MS). This parameter has been considered a good indicator to monitor neurological conditions. MS is a condition characterized by damaged neurons that induces inefficient communication between parts of the nervous system. It is believed that MS is caused by an autoimmune disorder and also environmental factors like infections.Ā Patients with MS are generally treated by numerous medications aimed to prevent new attacks and long-term disability. Alternative medicines including relaxation techniques, drugs like cannabis and oxygen therapy are also explored by MS patients despite the lack of scientific evidence. Patients with MS may suffer from various symptoms including muscle weakness/spasms, difficulty in moving and coordination, changes in sensation, depression, fatigue, bladder and bowel difficulties, and problems with speech. Some of these symptoms may develop in isolated attacks and some strengthen with time resulting in permanent neurological problems. Among these, visual problems related to inflammationĀ of theĀ optic nerve have been associated with MS and they may lead to complete or partial loss of vision. Retina, which constitutes theĀ third and inner coat of the eye, is reported to be an excellent site for monitoring neurological disorders like MS. OCT is a technique that is utilized to perform thickness measurements of the intra-retinal layers. Nonetheless, the approaches currently employed to determine layer thickness vary notably and published data concerning the reliability of OCT are not conclusive. In the study, researchers evaluated the repeatability of different estimated thickness using OCT technique. After in-depth literature search, 27 articles related to OCT applied to MS patients have been identified. To explore the repeatability of previously published estimates, the researchers performed repeated measurements on 13 MS patients and 15 healthy controls using two OCT devices. The team estimated each layer thickness with repeated measurements and looked at repeatability using correlation/repeatability coefficients. The results of the simulated layer thicknesses showed excellent repeatability for all retinal layers except for the outer plexiform layer, which is characterized by a thinner thickness. RELATED:Ā Mitochondria May Play a Role in MS Development and Progression Given the reliable and repeatable estimates obtained in the study, researchers concluded that the use of OCT should be encouraged in clinical research studies with MS patients especially for thicker retinal layers. However, for thinner ones as the outer plexiform layer of the retina, the assessment generally looks weak and hence requires a further investigation in the future. Print This Page About the Author Malika Ammam, PhD Malika Ammam received her MS degree from the University of Pierre et Marie CURIE in July 2002 and her PhD from the University of Paris Sud XI, France in September 2005. From 2006 to 2007, she worked as a research fellow at the University of Kansas in collaboration with Pinnacle Technology Inc. (USA). From 2007 to 2010, she was a research associate at KU Leuven, Belgium. From 2010 to 2012, she worked at the University of Ontario Institute of Technology in collaboration with Alcohol Countermeasure Systems Corporation, Canada. She held a prestigious Rosalind Franklin fellowship and resigned in 2015. Now, she is a freelancer. Tags multiple sclerosis, OCT, optical coherence tomography
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients